Accout Center s.r.o.

Šahy 93601

0 studies enrolling now · 11 studies all time

What they study most

Crohn Disease, Moderately to Severely Active Ulcerative Colitis, Ulcerative Colitis

Studies at this site

• A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (Also Known as RO7790121) in Participants With Moderately to Severely Active Ulcerative Colitis — Recruiting now
• ABTECT - Maintenance — Running, not enrolling
• Dose-Ranging Phase 2b Study of ABX464 in Moderate to Severe Ulcerative Colitis — Completed
• ABTECT-2 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -2 — Completed
• Open-Label Extension and Safety Study for Participants With Crohn's Disease Previously Enrolled in the Etrolizumab Phase III Study GA29144 — Stopped early
• Study for Participants With Ulcerative Colitis Previously Enrolled in Etrolizumab Phase II/III Studies — Stopped early
• The Efficacy and Safety of Cobitolimod in Participants With Moderate to Severe Active Left-Sided Ulcerative Colitis — Stopped early
• Etrasimod Versus Placebo as Induction Therapy in Moderately to Severely Active Ulcerative Colitis — Completed
• Etrasimod Versus Placebo for the Treatment of Moderately to Severely Active Ulcerative Colitis — Completed
• A Study to Assess Whether Etrolizumab is a Safe and Efficacious Treatment for Participants With Moderately to Severely Active Crohn's Disease — Completed
• A Study Comparing the Efficacy and Safety of Etrolizumab With Adalimumab and Placebo in Participants With Moderate to Severe Ulcerative Colitis (UC) in Participants Naive to Tumor Necrosis Factor (TNF) Inhibitors — Completed